Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Offers a Glimpse into its R&D Pipeline, Patent Strategies, and Clinical Trials at March Investor Conferences
- Mydecine participated in this year’s Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference, and will be at the upcoming Maxim Group’s Virtual Growth Conference
- These conferences represent an opportunity for the company to share its R&D pipeline, patent strategies and ongoing clinical trials
- Mydecine’s management has optimism for the future, as it taps into the growing psychedelics therapeutics and smoking cessation markets
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) has been at the forefront of developing novel psychedelic and non-psychedelic molecules for medical use. Its research and development efforts have focused on compounds that can enable safer and more effective treatments for patients dealing with conditions with unmet needs in mental health and addiction disorders.
Since its inception back in 2020, the company has made significant strides, not just in its research but also in its clinical trials. So far, it is the leading and only company in the industry that has an ongoing industry-sponsored clinical trial assessing psilocybin for nicotine addiction. Additionally, it is also pursuing other indications that include but are not limited to PTSD and anxiety.
Mydecine got to share these advancements at this year’s Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference as well as Maxim Group’s Virtual Growth Conference. It also walked attendants through its R&D pipeline and patent strategies.
The Roth Conference is renowned for its in-person experiences. Their March 2022 conference in Orange Country, California, let over 5,100 attendees in on Mydecine’s operations, providing one-on-one meetings with its management (https://ibn.fm/JG1TS)
The 32nd Oppenheimer & Co. Annual Healthcare Conference, also in March 2022, provided investors with an opportunity to interact with public and private healthcare companies in the healthcare industry, including Mydecine. The conference’s goal was to showcase nearly 300 companies that will likely shape the industry for the next decade to come. Mydecine stood out with its first- and second-generation novel therapeutics focusing on psychedelic compounds (https://ibn.fm/AoVdf)
The other March 2022 conference is Maxim Group’s Virtual Growth Conference (March 28-30), offering attendees a unique opportunity to interact with executives and institutional investors. The virtual event features company presentations, roundtable discussions, fireside chats, and live Q&A with Chief Executive Officers (“CEOs”). In addition, it represents an opportunity for Mydecine’s management to share its progress so far and offer a glimpse into what it has planned for the future (https://ibn.fm/HL2uP)
Mydecine, through its research, has positioned itself to capitalize on the opportunities in the industry, particularly with regards to psychedelic medicine for the treatment of mental health and addiction disorders.
Already, the psychedelics therapeutics market is projected to be valued at $66.5 billion by 2030, representing a CAGR of 8.2% over the forecast period. Additionally, the smoking cessation market is expected to post a CAGR of 16.9% to reach $64 billion by 2026 (https://ibn.fm/EWDWA)
Mydecine’s management is confident that with the investments made so far, coupled with the plans for the future, the company will capitalize on the industry’s growth, achieve significant progression and create value for its shareholders.
For more information, visit the company’s website at www.Mydecine.com.
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Mydecine participated in this year’s Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference, and will be at the upcoming Maxim Group’s Virtual Growth Conference
- These conferences represent an opportunity for the company to share its R&D pipeline, patent strategies and ongoing clinical trials
- Mydecine’s management has optimism for the future, as it taps into the growing psychedelics therapeutics and smoking cessation markets
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) has been at the forefront of developing novel psychedelic and non-psychedelic molecules for medical use. Its research and development efforts have focused on compounds that can enable safer and more effective treatments for patients dealing with conditions with unmet needs in mental health and addiction disorders.
Since its inception back in 2020, the company has made significant strides, not just in its research but also in its clinical trials. So far, it is the leading and only company in the industry that has an ongoing industry-sponsored clinical trial assessing psilocybin for nicotine addiction. Additionally, it is also pursuing other indications that include but are not limited to PTSD and anxiety.
Mydecine got to share these advancements at this year’s Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference as well as Maxim Group’s Virtual Growth Conference. It also walked attendants through its R&D pipeline and patent strategies.
The Roth Conference is renowned for its in-person experiences. Their March 2022 conference in Orange Country, California, let over 5,100 attendees in on Mydecine’s operations, providing one-on-one meetings with its management (https://ibn.fm/JG1TS)
The 32nd Oppenheimer & Co. Annual Healthcare Conference, also in March 2022, provided investors with an opportunity to interact with public and private healthcare companies in the healthcare industry, including Mydecine. The conference’s goal was to showcase nearly 300 companies that will likely shape the industry for the next decade to come. Mydecine stood out with its first- and second-generation novel therapeutics focusing on psychedelic compounds (https://ibn.fm/AoVdf)
The other March 2022 conference is Maxim Group’s Virtual Growth Conference (March 28-30), offering attendees a unique opportunity to interact with executives and institutional investors. The virtual event features company presentations, roundtable discussions, fireside chats, and live Q&A with Chief Executive Officers (“CEOs”). In addition, it represents an opportunity for Mydecine’s management to share its progress so far and offer a glimpse into what it has planned for the future (https://ibn.fm/HL2uP)
Mydecine, through its research, has positioned itself to capitalize on the opportunities in the industry, particularly with regards to psychedelic medicine for the treatment of mental health and addiction disorders.
Already, the psychedelics therapeutics market is projected to be valued at $66.5 billion by 2030, representing a CAGR of 8.2% over the forecast period. Additionally, the smoking cessation market is expected to post a CAGR of 16.9% to reach $64 billion by 2026 (https://ibn.fm/EWDWA)
Mydecine’s management is confident that with the investments made so far, coupled with the plans for the future, the company will capitalize on the industry’s growth, achieve significant progression and create value for its shareholders.
For more information, visit the company’s website at www.Mydecine.com.
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
